LINDA MUNSON: Open Payments
NPI 1477542561 · VALPARAISO, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,391 in 66 payments from 13 companies in 2025. Trend: 2023 $1,021 · 2024 $894 · 2025 $1,391
Food & beverage: $1,391
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 11 | $253 |
| Otsuka America Pharmaceutical, Inc. | 10 | $192 |
| Lundbeck LLC | 12 | $181 |
| Teva Pharmaceuticals USA, Inc. | 6 | $160 |
| Vanda Pharmaceuticals Inc. | 4 | $155 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $132 |
| Orexo US, Inc. | 5 | $106 |
| Axsome Therapeutics, Inc. | 4 | $65 |
| Alkermes, Inc. | 3 | $63 |
| E.R. Squibb & Sons, L.L.C. | 2 | $35 |
Products named: INGREZZA, ABILIFY MAINTENA, REXULTI, FANAPT, CAPLYTA, AUSTEDO XR, Zubsolv, Auvelity.
Industry payments across IN — which companies pay providers there.
